​Consideration of sex/gender aspects in cardiovascular clinical trials.

ABSTRACT:

Background

Understanding sex/gender in the context of health and disease is critical to deliver the best care. However, sex/gender have not been consistently considered in cardiovascular clinical trials. Global initiatives, including the Sex and Gender Equity in Research (SAGER)-guidelines, aim to improve the quality of the reporting, but it remains unclear if they are used consistently.

Methods

We conducted a systematic analysis of cardiovascular clinical trials published in PubMed between 2018 and 2024. To investigate the representation of women/females, we first analyzed the participation-prevalence-ratio (PPR). Second, we measured sex/gender-sensitive reporting (SGR) applying modified SAGER-guidelines. In addition, we determined whether study author sex/gender impacts th

SUBMITTER: Bley M 

PROVIDER: S-EPMC12708832 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature